Skip to content

Safety Articles

Latest articles, insights, and updates from the blog.

120 articles
Safety4 min read

Ketamine-Associated Hepatotoxicity: Risk Factors and Liver Function Monitoring

Review of ketamine-associated hepatotoxicity including risk factors, proposed mechanisms, liver function monitoring protocols, and clinical management for repeated therapeutic dosing.

Safety4 min read

Contraindications and Screening Protocols for Ketamine Therapy

A thorough guide to absolute and relative contraindications for low-dose ketamine, along with recommended screening protocols encompassing medical history, psychiatric evaluation, laboratory assessment, and informed consent procedures.

Safety4 min read

Ketamine Side Effects: A Complete Clinical Guide

Comprehensive evidence-based review of ketamine side effects including dissociation, nausea, cardiovascular changes, and cognitive effects for clinicians.

Safety4 min read

Cardiovascular Effects of Low-Dose Ketamine: Hemodynamic Monitoring Guidelines

Evidence-based hemodynamic monitoring guidelines for low-dose ketamine, covering sympathomimetic cardiovascular effects, blood pressure management, and cardiac risk stratification.

Safety4 min read

Cognitive Effects of Repeated Low-Dose Ketamine: Neuropsychological Assessment

Review of cognitive effects of repeated low-dose ketamine treatment, covering acute and chronic impacts on memory, executive function, and neuropsychological assessment strategies.

Safety4 min read

Can You Drive After Ketamine Treatment?

You should not drive for at least 24 hours after a ketamine infusion due to temporary cognitive and perceptual effects.

Safety4 min read

Abuse Potential of Therapeutic Ketamine: Risk Stratification and Monitoring

Assessment of abuse potential for therapeutic ketamine, examining risk stratification approaches, monitoring strategies, and safeguards for clinical prescribing programs.

Ready to learn more?

Explore our comprehensive guides and tools to help you navigate your ketamine therapy journey.